

Vincenzo Dadduzio

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3924787/publications.pdf>

Version: 2024-02-01

30
papers

614
citations

566801

15
h-index

580395

25
g-index

30
all docs

30
docs citations

30
times ranked

1412
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic impact of FGFR2/3 alterations in patients with biliary tract cancers receiving systemic chemotherapy: the BITCOIN study. <i>European Journal of Cancer</i> , 2022, 166, 165-175.	1.3	17
2	Association of <i>NOS3</i> and <i>ANGPT2</i> Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study. <i>Clinical Cancer Research</i> , 2020, 26, 4485-4493.	3.2	13
3	The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. <i>PLoS ONE</i> , 2020, 15, e0232449.	1.1	29
4	Videolaparoscopic microwave ablation in patients with HCC at a European high-volume center: Results of 815 procedures. <i>Journal of Surgical Oncology</i> , 2019, 120, 956-965.	0.8	19
5	Prevalence of pain in patients with cancer aged 70 years or older: A prospective observational study. <i>Journal of Geriatric Oncology</i> , 2019, 10, 637-642.	0.5	10
6	THU-448-Multicentric prospective study of validation of angiogenesis-related gene polymorphisms in hepatocellular carcinoma patients treated with sorafenib: Interim analysis of INNOVATE study. <i>Journal of Hepatology</i> , 2019, 70, e356.	1.8	0
7	Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition. <i>Clinical Colorectal Cancer</i> , 2019, 18, 125-132.e2.	1.0	35
8	Another Chapter of the Right Versus Left Story : Is Primary Tumor Location a Prognostic Feature in RAS Mutant Metastatic Colorectal Cancer?. <i>Oncologist</i> , 2019, 24, e77-e79.	1.9	3
9	Safety and Tolerability of Anti-Angiogenic Protein Kinase Inhibitors and Vascular-Disrupting Agents in Cancer: Focus on Gastrointestinal Malignancies. <i>Drug Safety</i> , 2019, 42, 159-179.	1.4	18
10	Bone metastases in biliary cancers: A multicenter retrospective survey. <i>Journal of Bone Oncology</i> , 2018, 12, 33-37.	1.0	5
11	Precision medicine in cholangiocarcinoma. <i>Translational Gastroenterology and Hepatology</i> , 2018, 3, 40-40.	1.5	61
12	Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol. <i>Tumori</i> , 2018, 104, 476-479.	0.6	14
13	Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase III CELESTIAL trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 207-207.	0.8	62
14	The interference between oxaliplatin & anti-EGFR therapies: a different hypothesis to explain the "unexplainable". <i>Personalized Medicine</i> , 2018, 15, 319-327.	0.8	2
15	Transarterial Chemoembolization with Small Drug-Eluting Beads in Patients with Hepatocellular Carcinoma: Experience from a Cohort of 421 Patients at an Italian Center. <i>Journal of Vascular and Interventional Radiology</i> , 2017, 28, 1495-1502.	0.2	40
16	Potential role of polymorphisms in the transporter genes ENT1 and MATE1 / OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2017, 86, 197-206.	1.3	22
17	Anti-EGFR monoclonal antibody panitumumab for the treatment of patients with metastatic colorectal cancer: an overview of current practice and future perspectives. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 1297-1308.	1.4	21
18	Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study. <i>ESMO Open</i> , 2017, 2, e000241.	2.0	10

#	ARTICLE	IF	CITATIONS
19	Cisplatin, dacarbazine and vinblastine as first line chemotherapy for liver metastatic uveal melanoma in the era of immunotherapy: a single institution phase II study. <i>Melanoma Research</i> , 2017, 27, 591-595.	0.6	28
20	Immunotherapy in Gastrointestinal Cancers. <i>BioMed Research International</i> , 2017, 2017, 1-17.	0.9	69
21	Partial splenic embolization in chemotherapy-induced thrombocytopenia: A retrospective analysis with long term follow-up.. <i>Journal of Clinical Oncology</i> , 2017, 35, e21654-e21654.	0.8	0
22	Simultaneous Care clinic (SCC): A three-year monoinstitutional experience.. <i>Journal of Clinical Oncology</i> , 2017, 35, 169-169.	0.8	0
23	Conversion Chemotherapy for Technically Unresectable Colorectal Liver Metastases. <i>Medicine (United States)</i> , 2016, 95, e3722.	0.4	18
24	Different EGFR Gene Mutations in Exon 18, 19 and 21 as Prognostic and Predictive Markers in NSCLC: A Single Institution Analysis. <i>Molecular Diagnosis and Therapy</i> , 2016, 20, 55-63.	1.6	22
25	Maintenance hormonal and chemotherapy treatment in metastatic breast cancer: a systematic review. <i>Future Oncology</i> , 2016, 12, 1299-1307.	1.1	16
26	KRAS Exon 2 Mutations as Prognostic Indicators in Advanced Colorectal Cancer in Clinical Practice: A Mono-Institutional Study. <i>Molecular Diagnosis and Therapy</i> , 2016, 20, 65-74.	1.6	7
27	Are TKIs favourable for the elderly with non-small-cell lung cancer?. <i>Oncotarget</i> , 2016, 7, 46871-46877.	0.8	7
28	Hormone Receptor Status and HER2 Expression in Primary Breast Cancer Compared With Synchronous Axillary Metastases or Recurrent Metastatic Disease. <i>Clinical Breast Cancer</i> , 2015, 15, 307-312.	1.1	66
29	K-RAS codon 13 mutation in advanced colorectal cancer: A single-center retrospective study investigating prognostic outcomes and treatment strategies.. <i>Journal of Clinical Oncology</i> , 2015, 33, 633-633.	0.8	0
30	Combined versus sequential adjuvant therapy of biliary tract cancer: What is the best option?. <i>Journal of Clinical Oncology</i> , 2015, 33, e15155-e15155.	0.8	0